% | $
Quotes you view appear here for quick access.

Immune Pharmaceuticals, Inc. Message Board

  • SortNewest  |  Oldest  |  Most Replied Expand all replies
    • This analysis from April have been on the Swedish board for a while.

      It is a dense input in the IL-2 arm discussion, from an ethical point of view.

      You find this under the chapter "Discussion":

      "The present meta-analysis has some limitations, including the fact that patient populations and doses/schedules of IL-2 varied widely across the trials included. However, the inability to demonstrate significant effects of IL-2 on LFS and OS in any of the individual trials and in all subsets analyzed here makes it unlikely that this treatment, when used as monotherapy for remission maintenance, provides meaningful benefits. A lack of effect of IL-2 was consistently observed across all subsets of patients grouped by the most important prognostic factors known for AML: age, karyotype category, AML cytological subtype, ECOG performance status, and time from CR to initiation of maintenance therapy. The type of induction therapy and its potential impact on any benefit of IL-2 maintenance therapy could not be analyzed here. Sex also had no impact on the lack of difference between IL-2 and controls, which is consistent with the absence of benefit observed across any other subsets."

0.210.00(0.00%)May 27 4:00 PMEDT